POAG surgical outcomes affected by DM

Article

According to recently published data, POAG patients with diabetes mellitus (DM) undergoing primary trabeculectomy with MMC do not achieve the same long-term IOP control compared to patients without DM.

According to recently published data, POAG patients with diabetes mellitus (DM) undergoing primary trabeculectomy with MMC do not achieve the same long-term IOP control compared to patients without DM.

Dr Simon K. Law, Glaucoma Division, Jules Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, California, USA, studied 41 eyes of 29 patients with DM and 81 eyes of 64 patients without DM. Patients with DM without retinopathy were retrospectively compared with a control group without DM. Surgical success was defined as IOP ≤15 and >5 mmHg without complications or further glaucoma surgery.

At 60 months the Kaplan–Meier cumulative survival rates were 57.8±9.3% for the DM group and 68.6±5.3% for the control group. Mean postoperative IOP of the control group was statistically significantly lower than the DM group at the two, three, six and seven-year follow-up visits. The rates of postoperative complications and additional glaucoma surgeries were the same between the two groups.

POAG patients with DM without retinopathy undergoing primary trabeculectomy with MMC could have a lower long-term surgical survival rate, compared to patients without DM.

The abstract can be read in the latest issue of the British Journal of Ophthalmology.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.